 CRANBURY, N.J., July 22, 2021 PRNewswire -- Palatin Technologies, Inc. Palatin NYSE American: PTN, a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced that Carl Spana, PhD, President and CEO of Palatin, presented today at the EyeceleratorASCRS Conference in Las Vegas, NV. 